Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression

Subjects Had Unipolar, Non-psychotic Major Depression Clinical Trial

Official title:

A Double Blind Pilot Trial to Evaluate Efficacy Trends and Safety of Risperidone and Olanzapine as add-on Therapy to Serotonin Type Antidepressants in Subjects With Treatment Resistant Depression (TRD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01282632
• Other study ID #: ro123
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: January 21, 2011
• Last updated: January 24, 2011
• Start date: August 2002
• Est. completion date: March 2004

Study information

• Verified date: September 2010
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Janssen Ortho Canada
• Study type: Interventional

Clinical Trial Summary

Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative efficacy and tolerability in treatment resistant depression. The current study was designed as a pilot study to examine efficacy and tolerability of Olanzapine vs. Risperidone add on to a failed serotonin re-uptake inhibitor (SSRI) in depression.

Description:

Overview of Study Design

This is a Canadian, multicentre, double blind, comparator trial in 42 patients with TRD. TRD is defined as the failure to respond adequately to two successive courses of different antidepressants at an adequate dose (at least fluoxetine 20 mg, citalopram 20 mg, paroxetine 20 mg, sertraline 100 mg, fluvoxamine 150 mg, venlafaxine 225 mg)) for at least 4 weeks. All subjects, at entry to the study will be currently not responding to treatment of at least 4 weeks duration of a serotonin re-uptake inhibitor (SSRI) or a selective nor-epinephrine and serotonin re-uptake inhibitor (SNRI). Non-response is defined as a score of 3 ("minimal improvement") or worse on the Clinical global Impression of Improvement .

The objective is to assess the appropriateness of the trial design and to determine sample size requirements for future controlled trials. In addition the efficacy and safety of oral doses of risperidone (.5-3 mg/day) and olanzapine (2.5-15 mg.day) as add-on therapy to any SSRI or SNRI in treatment resistant depression will be evaluated. Subjects meeting the screening criteria will enter a 6-week trial with risperidone or olanzapine added on to the current SSRI or SNRI therapy.

A medical/ psychiatric history, HAM-D-29 (only the first 17 items will be used for outcome), MADRS and HAM-A will be obtained at screening. At subsequent visits HAM-D, HAM-A, and MADRS will be performed and adverse events (spontaneous and using the CASES checklist) and concomitant medications will be collected.

Recruitment:

Subjects will drawn from two sources:

1. Outpatients currently attending the clinic at the sites. These subjects will already be in treatment or may have been referred from the local communities of the clinics involved in this study for consultation. Should these subjects drop out or once they have completed the study they will receive the treatment as usual at each site.

2. Advertisements. Advertisements will be placed in local media (radio, television, newspaper) identifying the nature of the study and providing a contact number. These advertisements will be approved by the local IRB's prior to posting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: March 2004
• Est. primary completion date: March 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Subjects who meet all of the following criteria are eligible for this trial:

1. Male or female out-patients;

2. Aged between 18 and 65 years (extremes included);

3. Subjects suffering from a current episode of non-psychotic, unipolar depression as determined by the depression section of the SCID-IV.

4. Subjects with treatment resistant depression defined as failure to respond to two successive courses of monotherapy given in adequate doses for a minimum of 4 weeks with different antidepressants (the current course of antidepressant can be considered to second failed course) and;

5. Subjects currently taking a SSRI or a SNRI for at least 4 weeks, at adequate dosage and not responding, as defined by a score of 3 or more on the CGI-I. and no dose change for 2 weeks prior to entry.

6. A minimum score of 16 on the 17 item HAM-D

7. Ability to provide informed consent.

Exclusion Criteria:

Subjects meeting one or more of the following criteria cannot be selected:

1. Subjects who are actively suicidal as determined by a score of 3 on the suicide item on the HAM-D or in the opinion of the treating physician;

2. Other current (active symptomatology within the last 2 months) Axis I DSM IV diagnosis other than nicotine or caffeine dependence or other than an Anxiety disorder.

3. Use of disallowed concomitant therapy; or other psychotropic medication except occasional benzodiazepines. (See "Rescue Medication");

4. History of alcohol or drug abuse or dependence, within 3 months of entry into the trial);

5. Seizure disorder requiring medication;

6. Active medical condition that requires urgent attention or that would contra-indicate the use of risperidone or olanzapine. For example stable thyroid disease or asthma would be acceptable, whereas acute hepatitis would not;

7. Participation in an investigational drug trial within 30 days prior to the start of the trial

8. Known sensitivity to risperidone, olanzapine or the antidepressant;

9. History of neuroleptic malignant syndrome (NMS);

10. Subjects who are at imminent risk of injury to self or others, or causing significant damage to property, as judged by the investigator;

11. Female subjects who are pregnant or breast-feeding;

12. Female subject of childbearing potential without adequate contraception (sterilization, barrier, IUD, oral contraceptives, intramuscular or subdermal administration of depot-progestagens);

15. Previous exposure to risperidone or olanzapine during the current episode.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Depressive Disorder, Treatment-Resistant
• Subjects Had Unipolar, Non-psychotic Major Depression

Intervention

Drug:
• Risperidone
Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
• Olanzapine
Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Hamilton Depression Rating Scale at 1 week	Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6.	day one	Yes
Primary	Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 1 week	MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6.	day one	Yes
Primary	Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 1 week	Impact on anxiety will be measured by the HAM-A over the 6 weeks.	day one	Yes
Primary	Change from Baseline in Hamilton Depression Rating Scale at 2 weeks	Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6.	day 8	Yes
Primary	Change from Baseline in Hamilton Depression Rating Scale at 3 weeks	Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6.	day 15	Yes
Primary	Change from Baseline in Hamilton Depression Rating Scale at 4 weeks	Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6.	day 22	Yes
Primary	Change from Baseline in Hamilton Depression Rating Scale at 5 weeks	Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6.	day 29	Yes
Primary	Change from Baseline in Hamilton Depression Rating Scale at 6 weeks	Subject to be eligible for this trial must have a minimum score of 16 on the 17 item HAM-D which will be obtained at screening. Efficacy will be measured on the HAM-D 17 and defined as a 50% decrease from baseline to week 6.	day 43	Yes
Primary	Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 2 weeks	MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6.	day 8	Yes
Primary	Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 3 weeks	MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6.	day 15	Yes
Primary	Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 4 weeks	MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6.	day 22	Yes
Primary	Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 5 weeks	MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6.	day 29	Yes
Primary	Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 6 weeks	MADRS will be obtained at screening. Efficacy will be measured by the MADRS and defined as a 50% decrease from baseline to week 6.	day 43	Yes
Primary	Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 2 weeks	Impact on anxiety will be measured by the HAM-A over the 6 weeks.	day 8	Yes
Primary	Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 3 weeks	Impact on anxiety will be measured by the HAM-A over the 6 weeks.	day 15	Yes
Primary	Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 4 weeks	Impact on anxiety will be measured by the HAM-A over the 6 weeks.	day 15	Yes
Primary	Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 5 weeks	Impact on anxiety will be measured by the HAM-A over the 6 weeks.	day 22	Yes
Primary	Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 6 weeks	Impact on anxiety will be measured by the HAM-A over the 6 weeks.	day 43	Yes
Secondary	Clinical Global Improvement Scale - Improvement	Subjects currently taking a SSRI or a SNRI for at least 4 weeks, at adequate dosage and not responding, as defined by a score of 3 or more on the CGI-I.	day one	Yes
Secondary	Change from Baseline of Weight at 6 weeks	Weight (Kg) will be measured with subjects at screening then at week 6.	day 43	No